ProMIS Neurosciences Inc (PMN)

[Phoenix300]

7.00 CAD
ProMIS has made it clear that they are seeking a partner for their -synuclein and TDP43 programs while the internal focus centers on the amyloid- and tau efforts. The company s unique platform to identify unique epitopes provides data that makes the therapeutic antibodies produced very valuable. Confidential discussions are currently underway with unidentified partners to develop these programs. In a recent presentation the company highlighted two deals in the hundreds of millions of dollars with Prothena / Roche and BioArctic / ABBVIE (in blue below) along with a comparison of candidates in the neurodegenerative space.
ProMIS is currently in confidential discussions with potential partners for the ALS and PD assets which may provide
capital via upfront payments to advance PMN310 into the clinic. An equity capital raise and significant investment
from a strategic partner are other mechanisms through which it can raise funds to advance the lead candidate.